JP2008519080A5 - - Google Patents

Download PDF

Info

Publication number
JP2008519080A5
JP2008519080A5 JP2007540384A JP2007540384A JP2008519080A5 JP 2008519080 A5 JP2008519080 A5 JP 2008519080A5 JP 2007540384 A JP2007540384 A JP 2007540384A JP 2007540384 A JP2007540384 A JP 2007540384A JP 2008519080 A5 JP2008519080 A5 JP 2008519080A5
Authority
JP
Japan
Prior art keywords
niacin
analog
composition
tetrazol
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007540384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/039560 external-priority patent/WO2006052569A1/en
Publication of JP2008519080A publication Critical patent/JP2008519080A/ja
Publication of JP2008519080A5 publication Critical patent/JP2008519080A5/ja
Pending legal-status Critical Current

Links

JP2007540384A 2004-11-05 2005-11-01 ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 Pending JP2008519080A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62553604P 2004-11-05 2004-11-05
PCT/US2005/039560 WO2006052569A1 (en) 2004-11-05 2005-11-01 Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists

Publications (2)

Publication Number Publication Date
JP2008519080A JP2008519080A (ja) 2008-06-05
JP2008519080A5 true JP2008519080A5 (cg-RX-API-DMAC7.html) 2008-12-25

Family

ID=36046632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540384A Pending JP2008519080A (ja) 2004-11-05 2005-11-01 ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物

Country Status (7)

Country Link
US (1) US20080139628A1 (cg-RX-API-DMAC7.html)
EP (1) EP1811996A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008519080A (cg-RX-API-DMAC7.html)
CN (1) CN101076331A (cg-RX-API-DMAC7.html)
AU (1) AU2005305086A1 (cg-RX-API-DMAC7.html)
CA (1) CA2584225A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006052569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ES2331521T3 (es) * 2003-11-21 2010-01-07 Arena Pharmaceuticals, Inc. Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo.
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
EP2099450A4 (en) * 2006-10-20 2011-01-26 Merck Sharp & Dohme AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
ES2566529T3 (es) 2008-07-08 2016-04-13 Daiichi Sankyo Company, Limited Compuesto heterociclilo aromático que contiene nitrógeno
AU2011270719B2 (en) * 2010-06-24 2015-09-24 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
CA2802952A1 (en) 2010-06-24 2011-12-29 Arisaph Pharmaceuticals, Inc. Niacin mimetics, and methods of use thereof
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US9456982B2 (en) 2014-05-18 2016-10-04 Be-Warm Llc Solid formulations of niacin to counteract cold extremities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20060167270A1 (en) * 2002-10-10 2006-07-27 Arena Pharmaceuticals Inc. 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
TWI258478B (en) * 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Similar Documents

Publication Publication Date Title
US6248745B1 (en) Pharmaceutical combination comprising a COX-2 inhibitor and a iNOS inhibitor
RU2188013C2 (ru) Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
CA2339661C (en) Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p
JP2011502958A5 (cg-RX-API-DMAC7.html)
JP2009533343A5 (cg-RX-API-DMAC7.html)
AU2008206231A1 (en) Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
JP2007520520A5 (cg-RX-API-DMAC7.html)
RU2014109079A (ru) Фармацевтическая композиция с маскированным вкусом
AU2011299153B2 (en) Methods for concomitant treatment of theophylline and febuxostat
US20110046190A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
RU2008138649A (ru) Применение а1-агонистов аденозина и/или двойных а1/а2в-агонистов аденозина для получения лекарственных средств для лечения заболеваний
JP2002522359A5 (cg-RX-API-DMAC7.html)
JP2006503850A5 (cg-RX-API-DMAC7.html)
JP2011519865A5 (cg-RX-API-DMAC7.html)
CA2602781A1 (en) 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法
CA2539985A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
JP2009533472A5 (cg-RX-API-DMAC7.html)
JP2009515927A5 (cg-RX-API-DMAC7.html)
JP2008534541A5 (cg-RX-API-DMAC7.html)
CA2402099A1 (en) Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment
WO2007103427A3 (en) Medical use of bilirubin and its structural analogues
CA2514373A1 (en) N-phenylbenzamide derivatives as drugs for the treatment of copd
JP2007538102A5 (cg-RX-API-DMAC7.html)
WO2009088006A1 (ja) 併用医薬